0001438133-26-000049
SEC filingGross margin improved to 55% on robust pump sales growth, despite a net loss of $20.4 million.
For the three months ended March 31, 2026, Tandem Diabetes Care reported total sales of $247.2 million, a 5.5% increase from $234.4 million in the same period of 2025. Growth was driven by a 10% rise in U.S. pump shipments (over 19,000 units vs. over 17,000 units) and improved average selling prices for supplies, partially offset by lower international pump volumes and distributor destocking in select European markets.
Gross profit increased 15.5% to $136.8 million from $118.4 million, with gross margin expanding 400 basis points year-over-year to 55%. The margin improvement was attributed to higher average selling prices, a favorable product mix (including a higher proportion of pump sales), foreign currency benefits, and lower material costs.
Operating expenses declined 35.6% to $154.2 million, primarily due to the absence of $75.2 million in acquired IPR&D charges incurred in Q1 2025. Excluding these and $11.2 million in one-time facility impairment and restructuring costs from the prior year, core operating expenses decreased modestly. SG&A expenses fell 5.0% to $108.2 million, as a $9.5 million investment in commercial infrastructure was more than offset by the non-recurrence of impairment and restructuring charges and lower stock-based compensation. R&D expenses declined 8.3% to $46.0 million, reflecting lower restructuring costs and reduced stock-based compensation, partially offset by higher clinical trial spending.
Net loss improved significantly to $20.4 million from $130.6 million, largely due to the one-time IPR&D charge in the prior year.
United States segment revenue grew 6.8% to $160.8 million, representing 65% of total sales within the quarter. Pump sales in the U.S. rose 8.0% to $77.9 million, while supplies and other revenue increased 5.6% to $82.9 million. The pharmacy channel contributed 6% of U.S. sales in Q1 2026 (versus immaterial in Q1 2025), reflecting the company's ongoing transition to a pay-as-you-go reimbursement model under pharmacy benefits.
International segment revenue increased 3.1% to $86.4 million, driven by favorable foreign exchange rates and a one-time benefit from transitioning rental customers from distributors in Switzerland. These gains partially offset lower pump shipments (over 10,000 vs. over 11,000) attributed to distributor destocking ahead of Tandem's initiation of direct sales in select countries. Distributor sales accounted for 89% of international revenue, down from 96% in the prior year.
Management's primary focus for 2026 is scaling the pharmacy benefit channel, which operates on a pay-as-you-go model. Under this structure, pumps are reimbursed through ongoing supply purchases at a price premium to the traditional DME model, eliminating upfront pump reimbursement. The company expects that as pharmacy utilization grows, lower upfront pump revenue will be offset by higher recurring supply sales and gross profit over the customer lifecycle, reducing seasonal volatility linked to insurance deductibles.
Liquidity remains strong with $570.3 million in cash and short-term investments, and positive operating cash flow of $11.1 million in Q1 2026. Management believes existing resources are sufficient to fund core operations for at least the next twelve months. The company also issued $291.2 million in 2032 convertible notes during the quarter, enhancing financial flexibility. No specific revenue or earnings guidance was provided.
At March 31, 2026, Tandem Diabetes held $179.3M in cash and cash equivalents and $390.9M in short-term investments, totaling $570.2M in liquidity. Total assets were $1,153.4M. The company's total debt consisted of $601.8M in convertible senior notes (net of issuance costs), comprising $316.3M of 1.50% notes due 2029 and $300.0M of 0.00% notes due 2032. Shareholders' equity was $132.4M, reflecting an accumulated deficit of $1,272.9M. Inventory stood at $126.4M, down slightly from $128.8M at year-end 2025.
Total undiscounted operating lease commitments were $170.0M as of March 31, 2026, with a present value of $133.0M. The weighted-average remaining lease term was 8.3 years. The company also had a $4.9M standby letter of credit related to one operating lease, expiring in 2035. No other material purchase commitments (e.g., supply agreements) were disclosed in the Notes.
During Q1 2026, Tandem issued $300.0M principal of 0.00% convertible notes due 2032, receiving net proceeds of $291.2M after debt issuance costs. The company used $15.3M to purchase capped call transactions to reduce potential dilution. There were no share repurchases or dividends. Capital expenditures totaled $6.3M (2.5% of sales), primarily for property and equipment. The 2029 notes remained outstanding with no repurchases or redemptions in the quarter.
The company operates as a single reportable segment: Insulin Pumps and Supplies. For Q1 2026, total sales were $247.2M, of which $160.8M (65%) came from the United States and $86.4M (35%) from international markets. Pump sales were $110.4M and supplies & other sales were $136.8M. The pharmacy channel accounted for 6% of U.S. sales. No individual international country exceeded 10% of total revenue.